RGNX - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to the REGENXBIO Second Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time.

As a reminder, this conference call is being recorded.

I would now like to turn the call over to Ms. President and Vice you for Berl, begin. may Garon of Policy Law REGENXBIO, Sara

Sara Garon Berl

thank joining Chief you us and Chief Medical afternoon Good for Vasista, Vit Ken Steve our our REGENXBIO’s Officer Dr. and today Officer. us Mills President Officer, and Executive Financial Pakola, Chief are With today.

at XX, call financial is release our development financial can and that press differ are reporting include risks outlook and financial results regarding REGENXBIO to in addition Earlier results forecasted uncertainties the plans. subject be The this regulatory to identified released afternoon, and conference X may product results those XXXX. expect, statements for cause other on and by www.regenxbio.com. Commission actual risks statements performance SEC’s These Management’s for Discussion should, XX-Q, uncertainties. risks our will, words such forward-looking REGENXBIO’s available report statements may, not words the of website and available operating forward-looking from will and of months and guarantees Today’s ended June our as to anticipate, forward-looking quarterly and believe, file XXXX, and the risk sections Any future the described is in of Analysis Form with certain Securities are Exchange the meaning. June intend plan, involve are similar on on quarter on which website. ended the and XX, and These factors such

or is make today’s be undertake recorded provided obligation on conference may Please account is X, this provide that only of forward-looking we information Any being call advised call future new on information, on any call statements and to of no call August webcast. events of the as we otherwise. XXXX this and update we date this

of is addition, and results not any positions may does to preliminary provided that forma be or unaudited project operating company. differ information materially. the Actual financial In purport financial may results pro or

Ken? our the turn over like now would call I REGENXBIO. to to

Kenneth Mills

Good provide conference We’ll recent for afternoon, Steve Sarah. provide joining will provide that on for our XXXX. today’s up of of you, financial our an second advancing everyone. NAV Platform. progress, then the us expanding of will internal and we recap Thank programs, call, clinical and thanks And a results an open will for quarter call update update questions. the on our Technology

past lives Over potential Platform. through improve of of the our remained therapy on course to the based mission REGENXBIO’s the decade, curative clear NAV gene proprietary has Technology

genetic modalities, with of rare utilize past two modalities single internal our productive to from treatment a our treatments have gene in and significantly committed treatments administration the course for We’ve expand we diseases, monogenic many are believe broadly develop public our alter these options treatment We work AV gene those can in and REGENXBIO. disease programs been patients advanced mind. for populations. diseases And suffering replacement. NAV antibody at delivery, therapy highly The on months to patient Technology affecting Both mediated health. several

pipeline that nervous we and deep our Technology, of a With areas, leverages across development over three XXX ophthalmology, therapeutic clinical system, broad vectors. distinct consists liver novel including NAV which directed, have AV central and programs

which positive study Our trial help ongoing remarks. in potentially patients. excited Wet his administered can Steve of onetime And gene product our address millions announce today, to Phase I/IIa a therapy RGX-XXX will RGX-XXX as treat treatment further we’re results candidate, for interim AMD, from

from to these dose forward of encouraged and data five in October. data new look sharing We’re interim by cohorts more all

NAV Novartis’ therapy, potentially spinal families In significant a progress Technology May important Our Technology, approved atrophy, facing milestone and a Zolgensma The and as first and gene therapy well. continue to the make gene for debilitating the Platform. FDA NAV of based muscular on partners licensee REGENXBIO’s deadly approval patients disease. marked

driven been breakthrough always execution for sound by of talented formula and success people, our science, has disciplined plans. capital REGENXBIO’s

in are gene therapies way commitment into decade reality has patients for to leader a transform global treated. transformed us Our the therapy that to diseases have gene developing of making the potential

driving and of time Technology chronic rare realize internal an an of for motivated the incredibly fullest ever exciting pipeline It’s expanding we’re diseases. as as therapy. the potential programs and Today, gene based to NAV we’re

So Steve turn clinical the I’d with to that, regulatory a now over like update. call to for and

Steve Pakola

RGX-XXX logic, to pleased of AMD, the treatment across I’m and the Japan. our U.S., I’ll that optimal Ken. Europe begin patients Thanks, X in directed more affects CNS disease programs wet in advances and a with internal program therapies. delivered than million share for

to wet frequently Continuing loss. patients with vessels with month therapeutic blood AAVX indefinitely the to is intraocular burden and NAV anti-VEGF a current to families require as to retina. under to AMD potentially patients anti-VEGF proliferation for many the the to leading therapy loss therapies, injections utilizes regimen, vector ultimately a a long-term therapy and vision vision every in fab overtime. struggle anti-VEGF and with treatment, trans of as gene, halt recommended an comply RGX-XXX encoding the Patients antibody usually prevent anti-VEGF deliver

surgery previously completed at and cohorts which wet eight trial required a XX% treatment in the anti-VEGF from no the after AMD subjects announced, and for of we RGX-XXX included X we durable at dosing one vitriol dosing year. of centers, patients at X and five of administration cohort reported As clinical year Phase single one U.S. injections leading intro RGX-XXX. XX X/Xa response of retinal cohort

through that today, free We continue XX injection patients to months. be these announced

particularly by anti-VEGF that trial. these difficult the to subjects prior We were given in and enrollment study frequent had results are treat, therapy encouraged in the this received to

see that dependent are doses. protein levels one dose all in report RGF-XXX expression we pleased across to month, at increases also We

data Type trial. from X data with we and cohort also this discuss interim had of We year. XX to FDA cohorts report to meeting October Phase a to clinical and in X expect months out plan B X the from our Xb Month,

wet this end trial, subjects the year. keeps evaluating in RGX-XXX of filing of for IND meeting, plan this which second Xb a of diabetic us outcome AMD on trial by initiate the this toward to half with our in Progress a the year. pleased X retinopathy are new Phase of track We in with a continues Phase

Phase or ongoing wet from is those selection. trial process support and the DR. be support RGX-XXX AMD trials safety to Manufacturing AMD enrollment wet in data both to will used X/Xa RGX-XXX for in

X/X Next I’ll subjects enrollment programs. in treatment for or gene have for programs treatment we program of monogenic cohort the directed and the turn Phase homozygous trial. directed of X CNS including familial liver to RGX-XXX screening of our our directed liver therapy and diseases, In hypercholesterolemia, initiated re clinical of the

to with prophylaxis corticosteroid second the from half X data of this We cohort in report year. interim expect

sites our continues. CNS to to the II, the Turning and screening additional in MPS for treatment programs, cohorts dose for the of step X/X first activation And Phase clinical of RGX-XXX dosing trial. study

the We half in year. expect to update this interim of second an present

I, For site of MPS subject and RGX-XXX, trial. are Phase treatment recruitment the activations the ongoing and for clinical additional X

of For expect RGX-XXX, foreign clinical for or first CLNX treatment IND file equivalent second this first-in-human the disease, an we year. trial for to half the the of in

to you forward progress. We And drive our programs updates will providing with diligent forward. these continue on to we look our work

With the over to turn that, I back Ken. call

Kenneth Mills

Steve. you, Thank

gene scientific updates has many as our market therapy extensive for these but also our by by therapy could RGX-XXX. especially the network. breakthrough treatments gene in only an through interim footprint innovation product – and REGENXBIO and potentially encouraged well candidates licensee scientific not very the product bring own space to for We’re new data in developed candidates our

an in FDA, by in candidates than development the by earlier, marketed ZOLGENSMA of currently being Licensees. approved it’s was XX clinical partnered active the Technology as June XX, Novartis' product candidates these has and the applied U.S. NAV vector as are And I more which XXXX, uses XX development of our AVVX product technology NAV been mentioned partner in

the worldwide the we Technology with movement This Pfizer a for be Technology portfolio, we strength the agreement announced by continue development of common and of month, the validates hereditary encouraged our with that ataxia, treatment most disorders. therapy to gene property Last new ataxia. in added License the we treatment and Friedreich's NAV intellectual commercialization of new Licensee further license a of for NAV

As data and application Technology the the efficacy programs the of space. advancement achieve validate they NAV broad further additional drive the therapy Platform milestones, and collectively licensee gene and progress that AAV provide safety of

refer earlier specific can issued for updates to our today press release partners. on You other external

me, will underway previously into finally, one our from up headquarters allow for Technology other construction at construct and And cell plan production facility announced we update our NAV will new announced leaders cGMP completed using of production be based touch scaled culture Maryland. Rockville, cGMP production process. The to XXXX platform land to and suspension vectors new our the to on in facility integrated is

stage gene ultimately and been to operational our be product highest programs meet to The global hold process us of facility utilizing quality standards and the The will manufacturing additional requirements in of priority people to XXXX. platform and is development research clinic patients. to will This the to this therapy plant creation designed capacity in more to of regulatory and for systems ourselves a the excellent late develop us we development to efficiently, advance our has our allow expected candidates. from be

manufacturing our vector which scale programs to of stage network require and late expect may capable We be large early supply. supporting

that, over for Vit? review of to to the call Vit, I’d like turn the financials. With

Vittal Vasista

shares included a common REGENXBIO's million cash, compared assets stock. in sheet. is as cash securities XX, a equivalents ended Prevail $XXX.X were million to Prevail's XXXX, million equivalents the December interests securities, REGENXBIO Therapeutics. value XXXX. as the million in $XXX,XXX Prevail marketable $XX.X of carrying Thank $XXX.X of June REGENXBIO Prevail, in XX, and Prevail in and of XXXX, marketable owns XX, had Prior other you, of Ken. June Cash, June and equity totaling on currently marketable X.XX and quarter to cash co-founder included balance XXXX, of securities consolidated equity with on IPO

Upon offset the June in months primarily securities of securities, gain and securities fair decrease subsequently the were million million during related six XX, of the IPO, marketable period, used net to at cash, in cash operating remeasured $XX.X XXXX, the completion reclassified equivalents attributable Prevail. ended unrealized equity $XX.X was the securities the marketable to Prevail's cash to marketable during and activities The of value. of partially by

primarily decrease Zolgensma. quarter non-recurring million license as attributable with June our by during was period, second amended The the was period Revenues second the AveXis. development and compared ended royalties The revenue as $XX.X XXXX during well months three quarter decrease partially XXXX. for recognized the during million XXXX, million net of recognized the sales for license to were of by from same on achieved license offset of milestones of to licensees resulting revenue $XX.X in exercised XX, under $X.X XXXX the agreement options,

royalties expect we of Commercial periods. increase commenced to second quarter Zolgensma of and sales the in in future XXXX,

We are also payment achievement eligible to milestone from in $X $XX.X AveXis net sales million the of cumulative upon of of receive a billion Zolgensma.

months development expenses was million clinical million costs and with same XXXX. $XX.X for and XXXX, Research laboratory The $XX.X trials to attributable external were increase costs, to and three manufacturing-related facilities ended compared XX, period personnel June the increase services. in for expenses and the conducting primarily associated

General same and the for other ended XXXX, XXXX. fees administrative June three was services. XX, million increase expenses were compared and million professional for attributable advisory personnel the costs The months period to increase and in $XX.X primarily to for $X.X

and income million, share, compared to basic share, June loss marketable for the XX, Prevail $XX.X ended months $XX.X XX, recognized the of or XX, XXXX, gain net during ended period. net Net three the XXXX. income per of securities the $X.X XXXX, and the for or net three ended $X.XX million June $X.XX REGENXBIO's unrealized million, includes was equity loss diluted $X.XX of months loss three per basic months diluted Net on for June

million Based expects securities in XX, current to December XXXX. and operating $XXX at as its least equivalents its REGENXBIO plan, cash, cash balance be of on marketable

With will to knee review upcoming the and XXXX call bend and turn final back Ken, that, milestones. the our provide thoughts to I

Kenneth Mills

company. To update Thanks, past today, Vit. what we That was better. for the period two I discussed highly Steve’s mark productive like quarter also, summarize the a although good update

the RGX-XXX advance AMD treatment development to through continue DR. and clinical We of for wet

those dose And continue additional free the for from expression we in on dependent share of shared update reported cohorts for RGX-XXX dose more cohort we interim RGX-XXX program XX the positive to AMD in of five new to observed all treated continues be increases five protein in cohorts. in months. Today, across wet We anti-VEGF to well which RGX-XXX interim the remain trial at XX% X October. injections we plan updates in all subjects tolerated.

trial in anticipated Phase Xb we In addition, start late excited remain for XXXX. about the the

IND for in new this We’re year. half file Phase in to second also our RGX-XXX retinopathy X track diabetic on a of trial of the

in programs for clinical pipeline continuing treatment progress includes includes research angioedema, also with of developing are RGX-XXX which neuro the expanding enrollment and hereditary new regulatory we collaboration RGX-XXX and Our for are immune.

a We’re Technology affecting strategic The delivery programs to treat to Platform include larger recent further AV new advancing rare also excited of populations approval on to mediated important validates was antibodies milestone ZOLGENSMA FDA treat that by NAV of therapy Novartis' NAV diseases. exciting our Technology. monogenic direction gene an based diseases

of steadfast decade we and improving of a lives to After and the gene curative remain committed effort through focus, dedicated therapy. potential

chosen cash this last strong excellent especially advanced unmet for investigators, to work of course, positioned clinical in employees, moment position, Before medical needs. people family and innovative trials. patient to significant with the inspired well we milestones, go partners, future our we’re to and partners of our patients to With clinical our therapies recognize Q&A, take participate and achieve every who science our in trial

the we’ll turn for the that, With call operator over questions.

Operator

Instructions] [Operator with Foroohar comes you. question from Leerink. first Thank SVB Our Mani

Your line is now open.

Mani Foroohar

Hey, how about thanks to the think a Novartis. quick around one royalty from question. the stream guys, financial taking Have

a and awarded royalty And Zolgensma go gross would revenue line not the breaking pan for at revenue revenue? you you’re where royalty or net single would royalty us revenue far. comfortable can bar You license would out? out You that the of what of break sales think not royalty – either reach independent guys doing you say you you it if as guys out so Could of you what royalty royalty to item? materiality Fas you you out threshold total break are tell

Kenneth Mills

guidance Hey, for the we the this and Vit And category when fraction had we’ve the quarter gap in and item just involved profit I with material quarters Mani. our of a reason basis the as that out terms or question. the think for that was cost a that. obviously, on that statement. Thanks we that royalty break ramp up occur, sales, described, received quarter, on period, in of the product associated next what also based will Yeah, licensing Zolgensma Novartis for for because – this number of occur better breakout over parallel as the recorded sales breakout several sales revenues of have to the we loss of when those of ramp not by sale really see the in cost of we’ll line will

Mani Foroohar

we And data many HoFH a like quick Great. see expect as first follow-up, many, how to the how approximately? patients a release day should at

Kenneth Mills

re-enrollment end data Well, what on end hopeful better NFX. have our cohort towards we’re of the been. for an we prophylaxis And year has that corticosteroid have of dose operating we’re has the the with year. sense at to a currently a schedule But on Cohort will that the progress X the of

Mani Foroohar

you. with guys. Great. I’ll back Thanks,

Kenneth Mills

Sure. Thanks.

Operator

Thank our you. with And Gena comes question Barclays. Wang next from

now open. Your is line

Gena Wang

mention increase regarding wet protein have increase? questions, I Thank in proportionally X, the and dependent AMD with you was correlated that Just a two you program? X that wondering dose should taking dose my cohort for expression? Can you

Kenneth Mills

increasing Gena, dose to have doses dependence cohorts been and us used that cohort the reported know, X. in cohort to means proportional from X you previously the

Gena Wang

Okay, saw double so then level? like you double if the the say dose, protein

Kenneth Mills

we time to show five by be able from those at all cohorts patients that one report across the month, Yeah, will that show mean will values data dependency.

Gena Wang

you is three said injection XX question free. another then And Okay. of ahead patients months

for injection you rescue just months prior you us is to And criteria also, rate this injection? XX us remind three could patients? what remind So the interview these then of can the for

Steve Pakola

for question. the Steve here. Gena, Thanks Hi,

when re-injection we key In X/Xa at of you’re rates So looking is use in Phase liberal a this criteria very you a therapy. trial, rejection had anti-VEGF question trial what it criteria.

fluid, if sees re-injection. basically, at decrease fluid acuity in a of acuity, So or any leading a due visual in a give to an principal discretion their in investigator decrease can to increase presence visual they

called tougher to bar you’d do note corrective important and re-injecting best that some increase, been compared to think XX very certain done visual decrease – later where I a or of have of or a criteria letter where that’s have decrease. stage what’s for micron studies example, So acuity a need, it’s you other that studies, for amount low

the gene of for cohort these we’re To patients got which results. part re-injection question, it subjects. months, also part case, re-injection these that’s we wouldn’t need injections before this exists this in treatment, of by only the didn’t the very And have your many needy if low second X in XX% after. that you these that’s encouraged is so they why not is XX much need anti-VEGF they So in trial. subjects needed expect therapy how bar of very any enrolled Not now critical, of it’s in many have anti-VEGF population these been a for for through face injections since

on needed part is or four the last months. year, So inclusion have In injections more one the average, chronically needed well, prior to as subjects RGX-XXX. last to within of the criteria, exclusion that eight patients injections point have receiving XX

on already entry right disclosed injections If there in we we having year a at prior fluid injection the cohort, injections, from population. on at of early in X it’s year, this previously XX some was for those the a there, it So average. needy look the fairly it’s study. of spite into still present anywhere cohorts And depending to

certainly anti-VEGF the on going how for October was all have update subjects prior as the we’ll cohorts of And when the in gene pre much well to will rate in put therapy. forward injection context updates on we this getting it

Gena Wang

the just Phase for the what line question final with you design, can ask Xb I If Could trial regarding you remind designed trial one FDA. say Xb? Great. in is Thank just us you quickly very Phase you much. more

Steve Pakola

Type Yeah, meeting, the presented we seen The later cohorts so main after Xb very when program today. we actual the had to now interim with give – actual we’re details the will design. outcome discussion the on Phase that a the our based B results say elements And study. on the and all constructive will we an year encouraged the our update we’ve Surprised in on FDA. of elements, five on trial of including design successful good we’ve update give the very more on results, main

guidance to with So we our by the end forward looking and than move our forward the starting study even confident, the before reiterating more feel very expeditiously actually of year.

Gena Wang

much. you very Thank Thanks.

Kenneth Mills

Thanks, Gena.

Operator

Thank you.

Harrison question next Matthew Stanley. comes from Our with Morgan

Your line is now open.

Unidentified Analyst

is advantages Thank [indiscernible] on have for this Hi, you. little you the could I currently a in competitive that of to a other development? bit Matthew. Costas talk RGX-XXX compared regarding are therapies question gene AMD, about

Kenneth Mills

are NAV Yeah, Hi, maybe highly that therapy. I’ll factor, treatment to Technology, has AAVX of AMD describe cells important and features the start some differentiators of that Steve color. which Ken. additional wet candidate, this I is including for can provide to is responsive the the selective and in think origination Steve product that our use anti-VEGF which of we other this course, be will the for retina want indications the several target

largest population his to, patients. also to or wet was response doses. and where, my treatment as hardest the you and have administration of on doses, in kind, enrolled alluding also a subretinal it according however AMD treat – that investigators, that’s Gena, the XX its of to of our have enrolled as and now subjects we’ve We’re And knowledge five completely referred trial the a of measure have to route number to to number is using initiated Steve

clinical study where of product for routed History for, for a that up standard So in lot and done pharmacology I delivery in worldwide others is important us really and good – a of AMD treat and Background what current supported work a but designing approval, by the AAV X/Xa retina, of patients. large to of administration this a advancing to stage sets of a true evaluate lot ourselves And hard of my safe wet RGX-XXX, Phase we’re also helps think of and view, a at Natural sort have the program collecting data. preclinical effective

we’re think kind, first results sustained response, which protein and now seeing And the what its of also dose expression. is I in is dependent

about not to after today delivered downstream we the wet the durability those dependent but company among time, evaluate And updates. XX using we the protein [indiscernible]. And and months, population five only across that in announced continue we’ll are to first protein therapy, gene AMD and if effective to XX for up increases expression, patients. the demonstrated, production been further for gene We follow cohorts, we’ve durability of and expression an looking therapy effect, protein first have expression talked all a clinical hour of previously has to we months,

Our for development. of there’s and us of we’re FDA, by into product program candidate of pharmacology administration clear supports the very product advance on need the wet robust. with engagement important later to characterized think, that I candidate, our based route patients it, in we’re interests. The the that with is to stages know, encouraged you us And, demonstrated no AMD. an in And candidate of well this this generating, evidence the product

Steve Pakola

think the very And we’re that. of add if ongoing, non-gene that where encouraged terms in the I that of programs developmental based to therapy it – are you

[indiscernible] need or I gene it’s with frequent indefinite validate is in a these still less game or all from modalities. anti-VEGF rejection moving therapy mean, all where the direction like example. terms less programs injection. other And But but frequent these they foundational changer. advances need and incremental yes, of, dosing, in are delivery just you for system, different the that’s and think still like I right these for confirm of potential refills platform show

being sustained is clinically, therapy, over prior a dosing and vector to have expression measures delivering anti-VEGF said getting need a standard protein gene setting shown that seen of shown for now approach between functional – the regard, dramatic link anatomic in we gold on reduction in time we’ve of in expression Ken durable these now the a and compared horizon outcome just thinking the patients. also the that we gene of that I longer And and is basis second and what a and

these So encouraged are results with move on quite to – based forward. we again,

Kenneth Mills

route Yeah, administration piece is, and which clinically, with work we preclinical RGX-XXX and did Hopkins, have Penn one to that’s profile of suppressive that administration where rule inflammation conditions. product and nor or preexisting patients we ocular now we Johns neutralizing any out to or prophylactically we’ve that candidate due to add route antibodies. and demonstrated don’t but risks do administer those the I probably need oral inflammatory of their to we other need we emerged establish the or And address immune a to medications, of anti-inflammatory otherwise or at

but we a provides clinically, path the a the much understand of to that clearer market product. path in opportunity pharmacology terms this So believe clear for that also

Unidentified Analyst

is helpful. so much. This Thank very you

Kenneth Mills

Sure, thanks.

Operator

Instructions] Leon [ph] Thank next Dan Raymond you. from James. Our with [Operator comes question

Your line open. now is

Unidentified Analyst

taking Thank the progress. you your for questions. And updates for the thanks clinical on

cohort injections for of me, number about of for mean XX on update other you X.X? said I think the us half one the First X, months could at

Steve Pakola

Well, readout, seeing but we all comfortable the one our coming for that now have we’ve consistent findings update. that we’re with updates year very saying providing quantitative what our I’m data seen at we’ll in October. in quantitative based is on the details in that October the cohorts

Unidentified Analyst

are the both cohorts the is be a clarify to co comments, release Okay. month And to can in from follow-up? in going the have five? four going I follow-up of something Or different six and terms press then between

Steve Pakola

month So very important. data six is we think

patients X, from a march course, when it’s if on. completion month we So forward October, will many of just announced at updating least six in of in we’re how you cohort matter of of X, cohort we date have recruitment

Unidentified Analyst

follow-up cohort or whether then I would was guess I not? a months Okay, longer X six asking have

Kenneth Mills

those said show by data already quantitative based October. we the across outcomes, the, where Yeah, and enrolled and X cohorts out with have to than month of will next What report patients, certainly package and dean is, clinical trial, first on six is And our cohort those started at exists. want patients XX dose best the of been six got months this possible relationship average we’ve that pharmacology announcement protein, between we is as dependency months. when the pharmacology longer as we announcement and comparisons the on where study to one time effect we clinical whole that we this much month the in which the interpretation for in we think the made

Unidentified Analyst

accelerate program. you’re Okay, one kind AMD study a on injectable the for a over like then traditional things AMD the the you the wet study parallel sounds interpreting implying dose of with out is which wet that from more and and basically Is DME since It on it? potentially approach right of DME figured should get path have or the registration am class. that I that interpreting

Steve Pakola

will AMD trial. Well, a disease development – for the driven retinopathy, anti-VEGF our diabetic separate based wet different the study, DR process. X although a Phase our retinopathy that separate from plan, data on we’ve have discussed We feel target it’s to anti start a a

doses the data that we for diabetic anti-VEGF I as tolerability that population, the all evaluation can different select of well programs across as think from precedent the help we that safety utilize have the a different enough know retinopathy been will in us retinopathy, done have to and that data. course,

retinopathy. As can’t diabetic in certainly a wet X by from far independently. as AMD the puts us already good with actual we of development, them to data of Phase we stage X/X advanced think think I the Phase study mean, position having it I But

Unidentified Analyst

medical the DR. be finally, versus then is going into just Yeah, to DME hosting flip you’re correct? for meeting, mind Right, to basically this October, so And my event sorry, a like an

Kenneth Mills

and, including process mean, team, that options I for with few completed our presentation, final evaluating we’ve a our along when Well, date. announce confirmed and are plan a upcoming we’ll to investigators decision an events that

Unidentified Analyst

Thank great. Okay, guys. you,

Kenneth Mills

Sure.

Operator

turn this queue in like to And the Mills for I’m at the closing you. any call back questions no to Ken time, Thank showing further I’d remarks.

Kenneth Mills

Have questions, a you to great and us, today. look Thanks, great joining we operator. everyone are night. had Those almost better for for the providing updates. with we Thanks than forward Thanks, further participating. updates

Operator

This and participation Ladies for you and day. conclude your on conference. just Everyone, thank all you have program today’s your a may great gentlemen, connect. does

REGENXBIO (RGNX) 8 Aug 192019 Q2 Earnings call transcript